BRIEF-Prometic Life Sciences confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
March 22 (Reuters) - Prometic Life Sciences Inc
* Confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
* Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
* Results further support PBI-4050's pharmacological activity and clinical benefits in patients
* PBI-4050 has demonstrated a "very good" safety and tolerability profile, with no drug-related serious adverse events Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.